News

  • 28 September 2011

    AstraZeneca Faslodex wins Japanese regulatory approval

    AstraZeneca has received Japanese regulatory approval for Faslodex (fulvestrant) 500mg, an oestrogen receptor antagonist for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer.

Close
Close
Close

Go Top